All In Biotech

Drug Trial Radar · NCT04994509

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,368 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,368

Actual

Start

Aug 30, 2021

Primary completion

May 27, 2024

Study completion Jan 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 25 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW). The primary objective of this study is to evaluate the efficacy of LEN and F/TAF for HIV-1 PrEP in AGYW at risk of HIV-1 infection.

Conditions

  • Pre-Exposure Prophylaxis of HIV Infection

Interventions

  • Oral Lenacapavir (LEN)Drug

    Tablets administered orally without regard to food

  • Subcutaneous (SC) Lenacapavir (LEN)Drug

    Administered via SC injections

  • F/TAFDrug

    Tablets administered orally

  • F/TDFDrug

    Tablets administered orally

  • Placebo SC LENDrug

    Administered via SC injections

  • PTM Oral LENDrug

    Tablets administered orally

  • PTM F/TAFDrug

    Tablets administered orally

  • PTM F/TDFDrug

    Tablets administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)Time frame: Incidence Phase Screening Visit (Day 1)
  2. Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened SetTime frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • Madibeng Centre for Research

    Brits, South Africa

  • Emavundleni Research Centre

    Cape Town, South Africa

  • Vuka Research Clinic

    Cape Town, South Africa

  • Desmond Tutu Health Foundation Clinical Trials Unit

    Cape Town, South Africa

  • Botha's Hill Clinical Research Site, HIV Prevention Research Unit

    Durban, South Africa

  • CAPRISA eThekwini Clinical Research Site

    Durban, South Africa

  • CAPRISA Vulindlela Clinical Research Site

    Durban, South Africa

  • MatCH Research Unit, Suite 1112, 11th Floor

    Durban, South Africa

  • Synergy Biomed Research Institute (SBRI)

    East London, South Africa

  • Setshaba Research Centre

    Gauteng, South Africa

  • Wits Reproductive Health & HIV Institute (Wits RHI)

    Johannesburg, South Africa

  • The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp Clinical Research Centre

    Klerksdorp, South Africa

  • Perinatal HIV Research Unit (PHRU) Soweto Kliptown

    Kliptown, South Africa

  • Phoenix Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit

    Kwa Zulu Natal, South Africa

  • Verulam Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit

    Kwa Zulu Natal, South Africa

  • Tongaat Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit

    Kwa Zulu Natal, South Africa

  • Chatsworth Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit

    Kwa Zulu Natal, South Africa

  • Qhakaza Mbokodo Research Clinic

    Ladysmith, South Africa

  • Africa Health Research Institute

    Mtubatuba, South Africa

  • The Aurum Institute: Pretoria Clinical Research Centre

    Pretoria, South Africa

  • The Aurum Institute: Rustenburg Clinical Research Centre

    Rustenburg, South Africa

  • Desmond Tutu Health Foundation - Masiphumelele Research Office

    Sunnydale, South Africa

  • The Aurum Institute: Tembisa Clinical Research Centre

    Tembisa, South Africa

  • CAPRISA Umlazi Clinical Research Site

    Umlazi, South Africa

  • FPD-DTHF Ndevana Community Research Site

    Vincent, South Africa

  • Makerere-Kalangala Clinical Research site

    Kalangala, Uganda

  • AMBSO Masaka Clinical Research site

    Kyotera- Masaka Region, Uganda

  • Makerere University- John Hopkins University (MU-JHU) Mityana Research Site (MU-JHU) Care Ltd

    Mityana Town, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.